Gynecologic Cancer
Conference Coverage
Superiority of Dose-Dense Chemo Upheld for Ovarian Cancer
Major Finding: With a median follow-up of 6.4 years, median overall survival was not reached with dose-dense paclitaxel-plus-carboplatin...
News
Washington Post Blasts Proliferation of ESAs for Anemia
News
Erlotinib Fails as Maintenance Therapy for Ovarian Cancer
Major Finding: Compared with observation, erlotinib did not significantly improve either progression-free survival (12.7 vs. 12.4 months) or...
Conference Coverage
Olaparib Defers Progression of Serous Ovarian Cancer - Again
Major Finding: Addition of olaparib concurrently to paclitaxel-carboplatin chemotherapy and as maintenance therapy reduced the risk of progression...
News
FDA Approves REMS for Long-Acting Opioids
News
FDA Warns of QT Prolongation with Ondansetron Dose
News
Fertility Preservation No Longer Experimental for Cancer Patients
News
Effective Second-Line Agents Identified for Anti-NMDA Receptor Encephalitis
Major Finding: A significantly greater percentage of patients with anti-NMDA receptor encephalitis recovered fully within 2 years following...
News
Adding Bevacizumab Doubles PFS in Hard-to-Treat Ovarian Cancer
Major Finding: Median progression-free survival was longer with bevacizumab and chemotherapy than with chemotherapy alone (6.7 vs.